Frontiers in Pharmacology· 2026Q1
Advanced hybrid-stabilized cinacalcet nanocrystals for enhanced oral bioavailability: formulation and integrated in vitro/in vivo evaluations
- 1citations
- Q1SCImago
- 2026year
Short summary
Advanced hybrid-stabilized nanocrystals (HNCs) of cinacalcet (CINA), a poorly soluble drug, achieved a 10.36-fold increase in peak plasma concentration (Cmax) and a 7.76-fold increase in area under the curve (AUC) compared to a conventional suspension.
AI-generated from the title and abstract; the full text is not read.
Key points
- Hybrid-stabilized nanocrystals (HNCs) were formulated for cinacalcet (CINA) using high-speed homogenization and a dual-stabilization strategy.
- The optimized HNC formulation had a particle size of 193.44 nm, PDI of 0.34, and saturated solubility of 2.04 mg/mL (1.8-fold increase).
- In vivo pharmacokinetic evaluation showed a 10.36-fold increase in Cmax and a 7.76-fold increase in AUC compared to a CINA suspension.
- The HNCs exhibited enhanced dissolution and good colloidal stability.
AI-generated from the title and abstract; the full text is not read.
Abstract
Introduction Cinacalcet (CINA), a Biopharmaceutics Classification System (BCS) Class IV drug, exhibits limited oral bioavailability due to poor aqueous solubility and low intestinal permeability. We aimed to mechanistically enhance the oral bioavailability of CINA through the development of advanced hybrid-stabilized nanocrystals (HNCs) prepared through high-speed homogenization. Methods A dual-stabilization strategy was implemented, combining a steric stabilizer (polyvinylpyrrolidone K90 or Pluronic® F-127) with a dispersing stabilizer (Tween® 80) to synergistically control nanocrystal formation, surface properties, and colloidal stability. A 2 1 ×·3 2 mixed factorial design was developed to investigate the effects of steric stabilizer type (Factor-A), total stabilizer concentration (Factor-B), and dispersing stabilizer contribution (Factor-C) on particle size (PS), poly-dispersity index (PDI), and saturated solubility (SS). Results Numerical optimization identified an optimal formulation exhibiting a PS of 193.44 nm, a PDI of 0.34, and an SS of 2.04 mg/mL, corresponding to a 1.8-fold increase compared with unprocessed CINA (1.10 ± 0.02 mg/mL). Furthermore, the optimized formula exhibited a zeta potential (ZP) of −24.25 ± 0.64 mV, indicating good colloidal stability. Transmission electron microscopy confirmed the formation of discrete, uniformly distributed nanocrystals with well-defined nanoscale morphology. The optimized formulation demonstrated markedly enhanced dissolution behavior in simulated gastric (pH 1.2) and intestinal (pH 6.8) media, alongside satisfactory zeta potential and physical stability. In vivo pharmacokinetic evaluation following oral administration revealed a substantial enhancement in systemic exposure, with 10.36- and 7.76-fold increases in peak plasma concentration (Cmax) and area under the plasma concentration–time curve (AUC), respectively, compared to a conventional CINA suspension. Conclusion Collectively, these findings highlight hybrid-stabilized nanocrystals as a promising strategy for improving the oral bioavailability of poorly soluble and poorly permeable drugs.
The authors' abstract, as published at the source. Frontiers in Pharmacology, 2026 · DOI ↗
Continue with a free account
Ask the paper: 3 free questions a day about this paper; save it, get its citation, new summaries every day for your field. Takeaways are Premium.
Continue free on the webSign in with Google or Apple; no card needed. You come back to this paper.
On your phone:
Field: Pharmaceutical Science
Pharmaceutical SciencePharmacology, Toxicology and Pharmaceutics